|
Acornex aims to develop and commercialize, primarily through corporate partnerships, pharmaceutical products with improved bioavailability based on proprietary molecular carrier technology which help overcome various biomembrane barriers, especially in the areas of critical health needs, for examples, brain cancers (by overcoming the blood-brain barrier), intractable degenerative neurological and neuromuscular diseases (by selectively targeting mitochondria), and hereditary diseases (by efficient non-viral gene delivery).
|
